abstract |
The present invention relates to the use of a series of etherlysophospholipids (ELPs) for the preparation of a medicament for the treatment of an inflammatory disease without causing adverse gastrointestinal side effects and/or without inhibition of phospholipase A2 and prostaglandin E2, as well as preventing or treating ulcerative conditions of the gastrointestinal tract. |